Interim report
Page 1
ABLIVA The first signs of efficacy seen in patients in our Phase 1b study strengthens KL1333 . Ellen Donnelly , CEO AIN Interim Report January - June 2021 Delivering mitochondrial health
Loading workspace
ABLIVA The first signs of efficacy seen in patients in our Phase 1b study strengthens KL1333 . Ellen Donnelly , CEO AIN Interim Report January - June 2021 Delivering mitochondrial health
Your watchlist and earnings event details are available after you sign in.